Purple Biotech
PPBT
12 hedge funds and large institutions have $1.77M invested in Purple Biotech in 2022 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 1 increasing their positions, 4 reducing their positions, and 1 closing their positions.
200% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 1
37% more call options, than puts
Call options by funds: $499K | Put options by funds: $364K
20% more funds holding
Funds holding: 10 → 12 (+2)
0% less ownership
Funds ownership: 0% → 0% (-0%)
57% less capital invested
Capital invested by funds: $4.09M → $1.77M (-$2.32M)
75% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$162K |
| 2 |
SM
Sabby Management
Miami Beach,
Florida
|
+$85.8K |
| 3 |
Group One Trading
Chicago,
Illinois
|
+$58K |
| 4 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$645 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
-$2.58M |
| 2 |
Morgan Stanley
New York
|
-$50.3K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$32.3K |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
-$25.2K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$3.23K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Point72 Asset Management
Stamford,
Connecticut
| $1.07M | -$25.2K | -39 | -3% |
|
|
2
Renaissance Technologies
New York
| $198K | +$162K | +251 | New |
|
|
SM
3
Sabby Management
Miami Beach,
Florida
| $105K | +$85.8K | +133 | New |
|
|
4
Group One Trading
Chicago,
Illinois
| $103K | +$58K | +90 | +225% |
|
|
5
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| $97K | -$32.3K | -50 | -29% |
|
|
WTB
6
Washington Trust Bank
Spokane,
Washington
| $65K | – | – | – |
|
7
Geode Capital Management
Boston,
Massachusetts
| $50K | – | – | – |
|
|
VVP
8
Venture Visionary Partners
Sylvania,
Ohio
| $43K | – | – | – |
|
|
9
Morgan Stanley
New York
| $31K | -$50.3K | -78 | -67% |
|
|
10
UBS Group
Zurich,
Switzerland
| $8K | -$3.23K | -5 | -33% |
|
|
IA
11
IFP Advisors
Tampa,
Florida
| $1K | – | – | – |
|
|
NSIM
12
North Star Investment Management
Chicago,
Illinois
| $1K | – | – | – |
|
|
AIM
13
ARK Investment Management
St. Petersburg,
Florida
| – | -$2.58M | -3,312 | Closed |
|
|
14
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | +$645 | +1 | New |
|
PPBT Hedge Fund Activity: Q1 2022 in Review
12 of the 6,341 institutional investors tracked by Wall St. Rank reported a position in Purple Biotech (PPBT) for Q1 2022, worth a combined $1.77M — down 57% from $4.09M a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new PPBT positions and 1 closed out — a net gain of 2 holders — while 1 added to existing stakes and 4 trimmed.
The largest buyer was Renaissance Technologies, opening a new position worth an estimated $162K. The largest seller was ARK Investment Management, exiting entirely with an estimated $2.58M sold.
- 12 institutional investors held Purple Biotech (PPBT) as of Q1 2022, up from 10 in Q4 2021.
- Funds reported $1.77M of Purple Biotech stock for Q1 2022, down 57% quarter-over-quarter.
- 3 funds opened new Purple Biotech positions in Q1 2022 and 1 closed out, a net change of +2 holders.
- The largest Purple Biotech buyer in Q1 2022 was Renaissance Technologies, an estimated $162K added.
- The largest Purple Biotech seller in Q1 2022 was ARK Investment Management, an estimated $2.58M sold.
Based on aggregated 13F filings for Q1 2022.